Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression.
CRISPR/Cas9
PD-1
adoptive T cell therapy
genetic engineering
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
07 03 2023
07 03 2023
Historique:
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Engagement of the inhibitory T cell receptor programmed cell death protein 1 (PD-1) associates with dysfunctional states of pathogen- or tumor-specific T cells. Accordingly, systemic antibody-mediated blockade of PD-1 has become a central target for immunotherapies but is also associated with severe toxicities due to loss of peripheral tolerance. Therefore, selective ablation of PD-1 expression on adoptively transferred T cells through direct genetic knockout (KO) is currently being explored as an alternative therapeutic approach. However, since PD-1 might also be required for the regulation of physiological T cell function and differentiation, the suitability of PD-1 as an engineering target is controversial. In this study, we systematically investigated the maintenance of T cell functionality after CRISPR/Cas9-mediated PD-1 KO in vivo during and after acute and chronic antigen encounter. Under all tested conditions, PD-1 ablation preserved the persistence, differentiation, and memory formation of adoptively transferred receptor transgenic T cells. Functional PD-1 KO T cells expressing chimeric antigen receptors (CARs) targeting CD19 could be robustly detected for over 390 d in a syngeneic immunocompetent mouse model, in which constant antigen exposure was provided by continuous B cell renewal, representing the longest in vivo follow-up of CAR-T cells described to date. PD-1 KO CAR-T cells showed no evidence for malignant transformation during the entire observation period. Our data demonstrate that genetic ablation of PD-1 does not impair functionality and longevity of adoptively transferred T cells per se and therefore may be pursued more generally in engineered T cell-based immunotherapy to overcome a central immunosuppressive axis.
Identifiants
pubmed: 36853939
doi: 10.1073/pnas.2200626120
pmc: PMC10013756
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Adaptor Proteins, Signal Transducing
0
Antibodies, Blocking
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200626120Subventions
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : SFB 1321/1—329628492 (PROJECT P17)
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : SFB-TRR 338/1 2021—452881907 (PROJECT A01)
Organisme : Deutsche Forschungsgemeinschaft
ID : FOR2830 (PROJECT 5)
Références
Oncotarget. 2017 Dec 27;9(4):5208-5215
pubmed: 29435173
Blood. 2011 Aug 4;118(5):1255-63
pubmed: 21653320
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Clin Cancer Res. 2013 Oct 15;19(20):5636-46
pubmed: 23873688
Sci Immunol. 2021 Jan 15;6(55):
pubmed: 33452106
Science. 2001 Jan 12;291(5502):319-22
pubmed: 11209085
Elife. 2020 Mar 31;9:
pubmed: 32228854
Nat Med. 2017 Feb;23(2):242-249
pubmed: 28067900
Biomed Pharmacother. 2020 Jan;121:109625
pubmed: 31733578
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Immunity. 2020 Nov 17;53(5):985-1000.e11
pubmed: 33128876
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
Cancer Immunol Immunother. 2019 Oct;68(10):1701-1712
pubmed: 31542797
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
J Immunol. 2011 Jun 1;186(11):6280-6
pubmed: 21525385
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
J Exp Med. 2015 Jun 29;212(7):1125-37
pubmed: 26034050
J Virol. 2006 Nov;80(22):11398-403
pubmed: 16956940
Nat Biomed Eng. 2019 Dec;3(12):974-984
pubmed: 31182835
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
pubmed: 27141885
J Clin Invest. 2006 Jun;116(6):1675-85
pubmed: 16710479
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Mol Med Rep. 2018 Feb;17(2):2083-2088
pubmed: 29207115
Nat Commun. 2019 Sep 11;10(1):4109
pubmed: 31511513
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Nat Immunol. 2020 Dec;21(12):1563-1573
pubmed: 33106669
Immunity. 2016 May 17;44(5):1052-68
pubmed: 27192569
Sci Transl Med. 2021 Oct 13;13(615):eaba6006
pubmed: 34644150
Nature. 2017 Dec 7;552(7683):121-125
pubmed: 29143824
Ann N Y Acad Sci. 2011 Jan;1217:45-59
pubmed: 21276005
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Virol. 2007 Apr;81(8):4215-25
pubmed: 17287266
Cell Rep. 2020 Jun 30;31(13):107827
pubmed: 32610128
PLoS One. 2013 Apr 09;8(4):e61338
pubmed: 23585892
Oncotarget. 2016 Nov 22;7(47):76902-76919
pubmed: 27708227
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Sci Rep. 2017 Apr 7;7(1):737
pubmed: 28389661
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
J Clin Invest. 2016 Nov 1;126(11):4262-4272
pubmed: 27760047
Trends Microbiol. 2018 Jun;26(6):498-509
pubmed: 29249600
Cancer Immunol Immunother. 2019 Mar;68(3):365-377
pubmed: 30523370
Clin Cancer Res. 2017 May 1;23(9):2255-2266
pubmed: 27815355
Immunity. 2014 Jul 17;41(1):116-26
pubmed: 25035956
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
Clin Cancer Res. 2014 Aug 15;20(16):4262-73
pubmed: 24919573
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8623-8
pubmed: 19433785
J Immunother Cancer. 2019 Nov 14;7(1):304
pubmed: 31727131
PLoS One. 2013;8(2):e56539
pubmed: 23409193
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
Cell Res. 2017 Jan;27(1):154-157
pubmed: 27910851
Front Pharmacol. 2018 Oct 01;9:1118
pubmed: 30327605